CurrentPremera BluecrossPolicy 2.04.509

Cardiovascular Risk Panels

Defines medical necessity and coverage stance for cardiovascular risk panels (multi-marker tests beyond simple lipid panels) offered commercially; lists examples, coding guidance for component tests, evidence summary, guidelines, and policy history for Premera Bluecross policy 2.04.509.

Policy Summary

PayerPremera Bluecross

PolicyCardiovascular Risk Panels

Policy CodePolicy 2.04.509

Change TypeClarified; Revised

Effective DateMar 1, 2026

Next Review Date

Key ActionProviders should be aware that cardiovascular risk panels (multi-marker panels beyond simple lipid panels) are considered not medically necessary and claims for such panels are subject to denial per policy.

SourceLink

POLICY UPDATE CHANGES

Removed CPT code 81291 from the policy as it is reviewed by Carelon.

Policy renumbered from 2.04.100 to 2.04.509.

1Coverage stance (not medically necessary)

12Example named panels listed

12Component CPT/PLA codes listed

Coverage Summary

This policy addresses commercial cardiovascular risk panels—multi-marker tests beyond simple lipid panels—and defines their coverage. The policy stance is not medically necessary for cardiovascular risk panels intended to assess cardiac risk (other than simple lipid panels). Effective date: Mar. 1, 2026; Last review: Feb. 23, 2026.

Medical Necessity Determination

Cardiovascular risk panels, consisting of multiple individual biomarkers intended to assess cardiac risk (other than simple lipid panels) are considered:

Cardiovascular risk panels consisting of multiple individual biomarkers intended to assess cardiac risk (other than simple lipid panels) are considered not medically necessary.

Examples include (but are not limited to)

Atherotech Diagnostics Lab CVD Risk Panel and VAP Lipid Panel
Boston Heart Cardiovascular Map Panels
CardioVIP/Spectracell Metabolic Characterization Panel
Genetiks Genetic Diagnosis and Research Center Cardiovascular Risk Panel
CV Health Plus Genomics Panel (Genova Diagnostics)
CV Health Plus Panel (Genova Diagnostics)
CVD Inflammatory Profile (Cleveland Heart Lab)
Cardio Check Profile (Genova Diagnostics)
MI-HEART Ceramides Panel (Mayo Clinic)
Quest Diagnostics Cardio IQ (advanced lipid panel)
Quest Diagnostics/Cleveland HeartLab inflammation testing (inflammatory biomarkers)
Quest Diagnostics The Advanced Heart Health Test Panel (with ApoB)
Singulex SMC Cardiac function and Inflammation testing
Veridia Diagnostics SMC cardiac function

Note: This policy does not address the use of panels of biomarkers in the diagnosis of acute myocardial infarction.

Definition of Simple Lipid Panel (Excluded from 'panel' restriction)

Simple lipid panel is generally composed of the following:

Total cholesterol

Low-density lipoprotein (LDL) cholesterol

High-density lipoprotein (HDL) cholesterol

Triglycerides

Certain calculated ratios, such as total/HDL cholesterol, may also be reported as part of a simple lipid panel.

Exclusions: Other lipid testing (apolipoproteins, lipid particle number/size, lipoprotein a, etc.) are not considered simple lipid panels.

Not Medically Necessary / Not Covered

Evidence shows many individual biomarkers and multi-marker panels demonstrate predictive associations with cardiovascular disease, but there are limited or no randomized controlled trials and a lack of outcome-based studies demonstrating that use of these multi-marker panels improves patient health outcomes beyond conventional risk assessment. The evidence conclusion is that there is insufficient evidence that cardiovascular risk panels improve net health outcome.

Major guideline bodies do not support routine use of bundled cardiac risk panels for primary prevention. Recent ACC/AHA and ESC/EAS guidance do not recommend routine use of bundled cardiac risk panels, although selective measurement of specific biomarkers (for example, hs-CRP, lipoprotein(a), or ApoB) or imaging (such as CAC scoring) may be considered in selected clinical situations.

Coding Guidance

Component CPT codes (may be reported for individual tests within panels)CPT

82465	Cholesterol, serum or whole blood, total.
82652	Vitamin D; 1,25 dihydroxy, includes fraction(s), if performed.
83090	Homocysteine.
83698	Lipoprotein-associated phospholipase A2 (Lp-PLA2).
83718	Lipoprotein, direct measurement; high density cholesterol (HDL cholesterol).
83721	Lipoprotein, direct measurement; LDL cholesterol.
83722	Lipoprotein, direct measurement; small dense LDL cholesterol.
83880	Natriuretic peptide.
84478	Triglycerides.
86141	C-reactive protein; high sensitivity (hsCRP).

1–10 of 12

1/2

Provider Actions

Denial Risk

Do not use panels for coverage

Providers should be aware that cardiovascular risk panels (multi-marker panels beyond simple lipid panels) are considered not medically necessary and claims for such panels are subject to denial per policy.

Billing Rule

Report individual component tests using appropriate CPT codes

There is no specific CPT code for cardiovascular risk panels; components may be billed using existing CPT codes listed in the policy.

82465
82652
83090
83698
83718
83721
83722
83880
84478
86141
0052U
0119U

Background and Definitions

Cardiovascular risk panels combine multiple biomarkers—lipids, inflammatory markers, metabolic markers, genetic variants, and sometimes imaging measures—in an effort to estimate cardiovascular disease risk. While numerous commercially available panels exist with varying components, the policy notes that most evidence demonstrates predictive performance of individual markers or panels rather than demonstrated clinical utility in changing management or improving outcomes.

Term	Definition
Cardiovascular risk panels
Combinations of multiple cardiac and noncardiac biomarkers intended to evaluate risk of developing cardiovascular disease, distinguished from simple lipid panels or single validated risk modifiers.
Simple lipid panel
Generally includes total cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides, and may include calculated ratios such as total/HDL.

Evidence conclusion: Insufficient evidence that cardiovascular risk panels improve net health outcome; predictive performance demonstrated but clinical utility not established.

Guideline consensus: Major societies (ACC/AHA, ESC/EAS) do not recommend routine use of bundled cardiac risk panels for primary prevention; selective use of certain biomarkers (for example, hs-CRP, Lp(a), ApoB) or imaging (CAC scoring) may be considered in specific situations.

Name	Type	Number	Effective
Medicare National Coverage
NCD

none